(Bloomberg) -- Eli Lilly & Co.’s relentless stock records have Morgan Stanley analysts musing whether it will become the first US company outside of the Magnificent Seven to reach a market value of $1 trillion.
The analysts lifted their price target on the weight-loss drugmaker to the highest on Wall Street on Friday, to a level that would take the market capitalization to about $900 billion, according to Bloomberg calculations.